What Happened

Gilead acquired global rights to PepStar Therapeutics' oral IL-23 receptor inhibitor program HCXT-2001 for $1.275 billion upfront. The asset is a phase 1 oral macrocyclic peptide designed for inflammatory diseases, with potential for all-oral combination therapy alongside Gilead's α4β7 inhibitor emvistegrast. Clinical trials are underway in China and New Zealand.

Who Is Affected

Gilead's R&D, clinical operations, and regulatory teams managing the HCXT-2001 integration are the primary stakeholders. Competitors J&J (Icotyde) and AbbVie (Skyrizi) will face a new entrant in the oral IL-23 space. Vendors providing clinical trial software, regulatory consulting, and CDMO services should target Gilead's program leads.

Market Impact

• Oral IL-23 competition heats up: Gilead enters a market currently led by J&J's Icotyde and AbbVie's injectable Skyrizi, with differentiation potential from less frequent dosing and combination therapy.
• Early-stage service demand: Phase 1 trials in multiple countries create opportunities for CROs, clinical supply chain, and regulatory support.
• Investor sentiment: BMO Capital Markets analysts welcomed the deal, noting it could strengthen Gilead's inflammation pipeline.

What to Watch

Phase 1 data from the food-effect and single-dose studies will be critical. Watch for updates on dosing frequency and combination feasibility with emvistegrast. Also monitor how Gilead integrates PepStar's program and scales manufacturing for the oral peptide.

Related coverage

• FDA approves Lilly's Jaypirca as first noncovalent BTK inhibitor for first-line CLL/SLL
• TRex Bio and Retension Pharmaceuticals file for IPO; ADARx eyes up to $446M listing
• Iambic Therapeutics raises $150M IPO to fund oncology pipeline and AI drug discovery platform
• AI biotech Iambic aims for $135M IPO to fund cancer drug clinical development